Why Is Echoiq (ASX: EIQ) Stock Dropping 13% Today?

Sonal Goyal

10 September 2026 05:56 PM AEST

Why Is Echoiq (ASX: EIQ) Stock Dropping 13% Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• EIQ shares fell 13.67% to $0.553 on 3 September 2026

• A further FDA application update for EchoSolv HF was provided on 8 September 2026, accompanied by an investor webinar

• EchoSolv HF is designed for heart-failure detection using artificial intelligence

• A global healthcare Investment professional has been appointed to the board

Echoiq Ltd (ASX:EIQ) shares fell 13.67% to $0.553 on 3 September 2026. The cardiac AI company's fortunes are closely tied to the outcome of its FDA application for EchoSolv HF, its artificial-intelligence technology for heart-failure detection.

Company Business

Echo IQ has been focused on the regulatory pathway for EchoSolv HF. The company submitted its FDA application previously and provided another FDA application update on 8 September 2026, accompanied by an investor webinar. The FDA rejected the initial clearance application for EchoSolv HF. Corporate developments also include the appointment of a global healthcare investment professional to the board, highlighting the company's U.S. commercial ambitions.

Sector Context

Heart failure is a significant global health burden, and AI-assisted echocardiography interpretation tools are attracting interest from health systems seeking to reduce diagnostic bottlenecks and improve early detection rates. FDA clearance is the critical gateway for any device or software targeting the U.S. healthcare market. For a company at Echo IQ's stage, the FDA review period is typically characterised by investor anticipation and share price Volatility tied to any update — positive or negative.

Risks to Consider

The FDA application remains pending, and clearance is not guaranteed. Any request for additional information from the FDA or an extended review timeline could affect investor sentiment and the company's commercialisation schedule. The 13.67% share price fall on 3 September 2026 suggests the market may be reassessing expectations around the application timeline. The appointment of a board member with global healthcare investment credentials is positive for governance but does not accelerate regulatory outcomes.

What to Watch Next

The outcome of the FDA application for EchoSolv HF

Content and market response to the 8 September 2026 investor webinar

Any further board or management appointments as the company prepares for potential U.S. market entry

Commercial Partnership announcements that might accompany or follow FDA clearance

Conclusion

Echoiq Ltd is in a critical regulatory phase as it awaits an FDA outcome for EchoSolv HF. The 13.67% share price decline on 3 September 2026 reflects the uncertainty investors assign to pending regulatory decisions. An updated FDA application statement and investor webinar were provided on 8 September 2026, and the market's response to that material will be closely watched.

Q1: What is EchoSolv HF?

Q2: Has Echo IQ received FDA clearance?

Q3: Why did EIQ shares fall 13.67% on 3 September 2026?

Q4: Who has been appointed to Echo IQ's board?

Q5: When is Echo IQ's next major catalyst?

All share price data as at 3 September 2026. Content is based strictly on company announcements, press releases and news releases. This article is for informational purposes only and does not constitute financial advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.